Evidence map›Paper›PMID 37108696›Full record

ReviewInternational journal of molecular sciences2023

Intimal Sarcoma with MDM2/CDK4 Amplification and p16 Overexpression: A Review of Histological Features in Primary Tumor and Xenograft, with Immunophenotype and Molecular Profiling.

Francisco Giner, Isidro Machado, Luis Alberto Rubio-Martínez, José Antonio López-Guerrero, Reyes Claramunt-Alonso, Samuel Navarro, Antonio Ferrández, Empar Mayordomo-Aranda, Antonio Llombart-Bosch

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Clinical activity of pembrolizumab in refractoryTherapeutic advances in medical oncology · 2024
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Francisco GinerPathology Department, University of Valencia, 46010 Valencia, Spain.ORCID 0000-0003-0765-7120
Isidro MachadoPathology Department, Instituto Valenciano de Oncología, 46009 Valencia, Spain.
Luis Alberto Rubio-MartínezPathology Department, Hospital Universitari i Politècnic La Fe of Valencia, 46026 Valencia, Spain.
José Antonio López-GuerreroMolecular Biology Department, Instituto Valenciano de Oncología, 46009 Valencia, Spain.ORCID 0000-0002-7369-8388
Reyes Claramunt-AlonsoMolecular Biology Department, Instituto Valenciano de Oncología, 46009 Valencia, Spain.
Samuel NavarroPathology Department, Hospital Clínic Universitari, 46010 Valencia, Spain.
Antonio FerrándezPathology Department, Hospital Clínic Universitari, 46010 Valencia, Spain.
Empar Mayordomo-ArandaPathology Department, Hospital Universitari i Politècnic La Fe of Valencia, 46026 Valencia, Spain.
Antonio Llombart-BoschPathology Department, University of Valencia, 46010 Valencia, Spain.
Fundación Instituto Valenciano de Oncología · ESHospital Universitari de Vic · ESHospital Universitari i Politècnic La Fe · ESUniversitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intimal sarcomas (IS) are rare malignant mesenchymal tumors arising in large blood vessels of the systemic and pulmonary circulation and also in the heart. They are morphologically similar to other spindle cell, poorly differentiated sarcomas. The prognosis is poor and depends mainly on surgical options. Three cases of IS were collected from two institutions. Clinical data were retrieved and histological study was performed. A wide immunohistochemical panel was analyzed. FISH of

Indexed as

SarcomaSoft Tissue NeoplasmsBiomarkers, TumorCyclin-Dependent Kinase 4Gene AmplificationHeterograftsHumansMutationProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-mdm2Proto-Oncogene Proteins p21(ras)Receptor Protein-Tyrosine KinasesBiomarkers, TumorCDK4 protein, humanCyclin-Dependent Kinase 4MDM2 protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-mdm2Proto-Oncogene Proteins p21(ras)Receptor Protein-Tyrosine Kinasesimmunohistochemistryintimal sarcomamolecular alterationstherapeutic targets

Identifiers

PMID37108696
PMCPMC10141691
OpenAlexW4366581761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.